Seeking Alpha

Harvard Bioscience completes regenerative medicine device spin-off

  • Harvard Bioscience (HBIO) is off 16% premarket after completing a spin-off of its regenerative medicine device subsidiary.
  • Harvard Apparatus Regenerative Technology now trades on the Nasdaq under the ticker HART.
  • HBIO shareholders got one share of HART for every share of HBIO they owned as of October 21.
  • HBIO now calls itself a "pure-play global developer, manufacturer and marketer of a broad range of tools to advance life science research." (PR)
  • CEO Jeffrey Duchemin has been appointed President and Director, replacing David Green who is now HART's President.
Comments (6)
  • I think some of this information is inaccurate. I owned 800 shares of HBIO up until close of business on October 22nd. I did not receive any shares of HART.
    4 Nov 2013, 08:52 AM Reply Like
  • 1 share of HART for every 4 shares of HBIO they owned
    4 Nov 2013, 08:58 AM Reply Like
  • I did hold till 31st Oct but have not received any shares yet
    4 Nov 2013, 09:40 AM Reply Like
  • Why the sell-off in HBIO? Buying opp?!
    4 Nov 2013, 09:51 AM Reply Like
  • idkmybffjill,

     

    it's not exactly a sell off. the capitalization value is less because the company no longer includes HART.

     

    considering the distribution of HART shares at 1:4, HART market cap should be worth 20% that of HBIO. Respectively, HBIO would be worth 20% less now than before.

     

    i am long--but wouldn't buy HBIO right now. statistically speaking, spinoffs do better than the parent company post-split.
    5 Nov 2013, 09:50 PM Reply Like
  • Not always Elias. Usually, but not always.

     

    In this case, the parent company's profitability was masked by the spinoff's lack of profitability.
    6 Nov 2013, 08:29 PM Reply Like
DJIA (DIA) S&P 500 (SPY)